eFFECTOR Therapeutics, Inc.
EFTR
$0.00
Change (1 day)
$17.90
Year High
$0.00
Year Low
Categories
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
eFFECTOR Therapeutics, Inc. (EFTR) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 5.67 M | 26.34 M | 20.54 M | 19.84 M | |
| 2022 | 11.57 M | 25.18 M | 29.08 M | 28.01 M | |
| 2021 | -29,672,000 | 36.77 M | 54.06 M | 52.9 M | |
| 2020 | -2,255,000 | 148.95 M | 16.7 M | 16.58 M | |
| 2019 | 11.82 M | 18.93 M | 5.1 M | 4.27 M |